2025-03-12 19:30:40
Latest Post
W S Industries India Ltd's subsidiary to acquire 54.89 acres land for Rs. 46.66 crores
IKS Health wins Top Honors in 2025 Black Book Survey in New AI-Driven RCM Category
Mipco Seamless Rings Gujarat Ltd approves shifting of registered office
Crizac Limited gets Sebi Nod for Rs 1,000 cr IPO
REC Limited inaugurates REC Experience Center
Stock Report
Kilitch Drugs India Ltd reports consolidated PAT of Rs. 3.56 crores in Q4 FY23
Posted On : 2023-05-31 18:12:03( TIMEZONE : IST )
Kilitch Drugs (India) Limited has reported Consolidated financial results for the period ended March 31, 2023.
Financial Results (Q4 FY2023) - QoQ Comparison
The company has reported total income of Rs. 46.4974 crores during the period ended March 31, 2023 as compared to Rs. 30.6589 crores during the period ended December 31, 2022.
The company has posted net profit / (loss) of Rs. 3.5637 crores for the period ended March 31, 2023 as against net profit / (loss) of Rs. 2.3707 crores for the period ended December 31, 2022.
The company has reported EPS of Rs. 2.29 for the period ended March 31, 2023 as compared to Rs. 1.52 for the period ended December 31, 2022.
| Financials | Q4 FY2023 | Q3 FY2023 | % Change |
| Total Income | ₹46.4974 crs | ₹30.6589 crs |  51.66% |
| Net Profit | ₹3.5637 crs | ₹2.3707 crs | 50.32% |
| EPS | ₹2.29 | ₹1.52 | 50.66% |
Financial Results (Q4 FY2023) - YoY Comparison
The company has reported total income of Rs.46.4974 crores during the period ended March 31, 2023 as compared to Rs.36.9858 crores during the period ended March 31, 2022.
The company has posted net profit / (loss) of Rs.3.5637 crores for the period ended March 31, 2023 as against net profit / (loss) of Rs.2.8982 crores for the period ended March 31, 2022.
The company has reported EPS of Rs.2.29 for the period ended March 31, 2023 as compared to Rs.1.86 for the period ended March 31, 2022.
| Financials | Q4 FY2023 | Q4 FY2022 | % Change |
| Total Income | ₹46.4974 crs | ₹36.9858 crs | 25.72% |
| Net Profit | ₹3.5637 crs | ₹2.8982 crs | 22.96% |
| EPS | ₹2.29 | ₹1.86 | 23.12% |
Financial Results (Year Ended FY2023) - YoY Comparison
The company has reported total income of Rs.142.5170 crores during the Financial Year ended March 31, 2023 as compared to Rs.117.1435 crores during the Financial Year ended March 31, 2022.
The company has posted net profit / (loss) of Rs.10.4481 crores for the Financial Year ended March 31, 2023 as against net profit / (loss) of Rs.7.3673 crores for the Financial Year ended March 31, 2022.
The company has reported EPS of Rs.6.71 for the Financial Year ended March 31, 2023 as compared to Rs.4.73 for the Financial Year ended March 31, 2022.
| Financials | Year Ended FY2023 | Year Ended FY2022 | % Change |
| Total Income | ₹142.5170 crs | ₹117.1435 crs | 21.66% |
| Net Profit | ₹10.4481 crs | ₹7.3673 crs | 41.82% |
| EPS | ₹6.71 | ₹4.73 | 41.86% |
Shares of Kilitch Drugs (India) Limited was last trading in BSE at Rs. 211.80 as compared to the previous close of Rs. 213.70. The total number of shares traded during the day was 3255 in over 55 trades.
The stock hit an intraday high of Rs. 219.95 and intraday low of 203.50. The net turnover during the day was Rs. 688230.00.
